Barclays Maintains an 'Overweight' on CVS Caremark (CVS); 3Q11 Earnings Preview

Barclays maintains an 'Overweight' on CVS Caremark (NYSE: CVS) price target of $44.00.

Barclays analyst says, "We are maintaining our 3Q11 operating EPS estimate of $0.66, $0.01 lower than consensus. Our GAAP EPS estimate is $0.61. We forecast total revenues to increase 12.2%, with retail rising 3.0% (on comps of 1.8%) and PBM sales growing 25.9%. Our total company operating margin is forecast to decrease by 62 bp, with 8 bp of expansion in retail and 123 bp of contraction in the PBM."

CVS will report 3Q11 results the morning of Thursday, November 3, and will host a conference call at 8:30 AM (EDT).

For more ratings news on CVS Caremark click here and for the rating history of CVS Caremark click here.

Shares of CVS Caremark closed at $36.33 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• Oppenheimer Reiterates Outperform Rating on NVIDIA (NVDA) Into EPS
• Goldman Sachs Downgrades Shanghai Jahwa United (600315:CH) to Neutral